Use of genetic variants in wnt signaling pathway to predict gender and tumor location dependent survival in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and bevacizumab (BEV).

Authors

null

Yan Ning

University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

Yan Ning , Wu Zhang , Dongyun Yang , Fotios Loupakis , Takeru Wakatsuki , Sebastian Stintzing , Nico Benjamin Volz , Joseph Ethan Li , Rita Elie El-Khoueiry , Melissa Janae Labonte , Chiara Cremolini , Federica Marmorino , Afsaneh Barzi , Anthony B. El-Khoueiry , Heinz-Josef Lenz , Michael Kahn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Citation

J Clin Oncol 31, 2013 (suppl; abstr 3568)

DOI

10.1200/jco.2013.31.15_suppl.3568

Abstract #

3568

Poster Bd #

5B

Abstract Disclosures

Similar Posters